Recognizing cancer diseases at an early stage: Researchers develop label-free automatic cancer diagnostics

October 25, 2013
pectral histopathology: Fourier transform infrared (FTIR) and Raman imaging analyses of tissue sections of a colorectal carcinoma (colon tumour). Image magnification increases from the top down. A classic H&E-(haematoxylin-eosin)-stained section is shown on the right. FTIR imaging (left) achieves a resolution of ten micrometres at maximum; spectral histopathology reveals the existence of alterations in the crypts (red), i.e. depressions in the colon, which are confirmed by immunohistochemical fluorescent stain (P53). In order to analyse the crypt alterations in more detail, the researchers applied Raman imaging with a higher spatial resolution (bottom row). Altered nuclei (grey) in the altered crypts (red) can be identified here in comparison with a fluorescent stain (P53, green). Credit: RUB, picture: Faculty of Biophysics

Researchers at the Ruhr-Universität Bochum (RUB) have developed a new spectroscopic method to support pathologists in diagnosing cancer. In the Journal of Biophotonics and the Analyst they compared conventional procedures for colon cancer identification with a novel method called label-free spectral histopathology. "Contrary to previous methods we no longer have to stain the tissue in order to detect cancer," says Professor Klaus Gerwert from the Protein Research Unit Ruhr within Europe (PURE) at the RUB. "In the future, this will give us the opportunity to classify a tissue sample automatically as being either normal or diseased."

Diagnosis: Colon cancer

Today pathologists slice tissue obtained from biopsies into thin sections, stain them chemically, and eventually identify by visual inspection under the microscope. This is usually done at an advanced stage of the disease, and the method provides no information about the molecular causes of the tumour. However, the method of spectral histopathology (SHP) established at the RUB Department of Biophysics captures molecular alterations directly in the tissues, especially changes of proteins. It works without any labelling agents, such as fluorescent dyes. SHP may even detect alterations occurring in early tumour stages. Since the analysis uses light beams, SHP is not limited to thin sections of biopsy specimens – in fact, one can apply the method directly in live tissue, where it allows to inspect a site of interest with the aid of fibre-optics. "In the future, we intend to work together with clinical partners and apply spectral histopathology to patients directly via endoscopes," says Klaus Gerwert.

How spectral histopathology works

In SHP, researchers record spatially resolved vibration spectra of a tissue using either an infrared or a Raman microscope. A vibration spectrum reflects the condition of all proteins in a tissue at the site measured. Alterations induced by cancer are reflected in the respective spectrum. The spectrum is thus representative of the status of the sample, just like a fingerprint is characteristic of an individual person. Approximately ten million infrared spectra are usually recorded to produce one single tissue image. Using sophisticated computational image analysis procedures, researchers compare these spectra with a reference database. This database contains spectra of already known tissues and tumours, and has been established in the PURE consortium as a collaboration between pathologists, biophysicists and bioinformaticians. The analytical programme allocates each spectrum to tissue types that have been stored in the database, represented by a specific colour—just like an offender who can be identified by comparing his fingerprints with previous database entries. This produces a spatially resolved annotated image of the colon tissue section. Both PURE members, Professor Andrea Tannapfel, Director of the Pathology Institute at the RUB, and Professor Axel Mosig, Head of Bioinformatics at the Department of Biophysics, made the essential contributions in creating the database and the evaluation algorithm. By now, the evaluation programme will run on any commercial laptop.

A spectrum as a biochemical fingerprint: By applying Fourier transform infrared and Raman imaging the RUB team obtains a "spectral fingerprint". It reflects the momentary condition of the cell on the level of proteins. Comparison with a "reference card index" makes it possible to allocate a "fingerprint" to a matching "suspect", for example, a colon tumour. Credit: RUB, picture: Faculty of Biophysics

Comparison with conventional tumour detection methods

In order to test the sensitivity and specificity of spectral histopathology, the RUB team compared SHP with classical immunohistochemical methods, in which tumours are identified with the aid of fluorescent labels. "The results match perfectly. It demonstrates impressively that spectral histopathology is capable of determining changes in tissue composition with high sensitivity and in an automated fashion," says Prof Gerwert. In fact, sensitivity and specificity of the method exceed 95 per cent. By extending their method to include Raman imaging, the RUB team achieved a higher spatial resolution than they could with infrared imaging, however, at the cost of prolonged measurement time. "Both methods complement each other excellently," comments Klaus Gerwert. "Infrared spectroscopy gives you a rapid overview of the entire section. We can then analyse suspicious regions in more detail by applying Raman imaging." Raman analysis, for example, reveals altered nuclei which are characteristic of tumours.

Explore further: 'Fingerprinting' breakthrough offers improved brain tumour diagnosis

More information: Kallenbach-Thieltges, A. et al. (2013): Immunohistochemistry, histopathology and infrared spectral histopathology of colon cancer tissue sections, Journal of Biophotonics. DOI: 10.1002/jbio.201200132

Mavarani, L. et al. (2013): Spectral Histopathology of colon cancer tissue sections by Raman imaging with 532 nm excitation provides label free annotation of lymphocytes, erythrocytes and proliferating nuclei of cancer cells, Analyst. DOI: 10.1039/C3AN00370A

Related Stories

'Fingerprinting' breakthrough offers improved brain tumour diagnosis

September 21, 2012
(Medical Xpress)—UK scientists have made a breakthrough in a new method of brain tumour diagnosis, offering hope to tens of thousands of people.

New method to test breast lesions could better detect cancer, save money by reducing repeat biopsies

May 31, 2013
A newly developed, single-step Raman spectroscopy algorithm has the potential to simultaneously detect microcalcifications and enable diagnosis of the associated breast lesions with high precision, according to data published ...

New method for early detection of colon cancer

September 4, 2013
A new, highly sensitive method to detect genetic variations that initiate colon cancer could be readily used for noninvasive colon cancer screening, according to a study published in Cancer Prevention Research, a journal ...

A promising new method for the diagnosis of breast cancer

October 24, 2013
According to a study that has just been published, a novel mammography procedure developed at the Paul Scherrer Institute (PSI), in cooperation with the Certified Breast Centre of the Kantonsspital Baden and the industrial ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.